Clinical Trial

Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy

Study acronym: DECLAM
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 10, 2024 (before its estimated November 11, 2024 completion). Its status may not reflect the trial's current state.
Summary
Neutropenia after induction or consolidation therapy for acute myeloid leukemia (AML) patients is associated with a high morbi-mortality rates, especially due to infectious complications. These are managed according to international recommandations (ECIL and IDSA) with antibiotherapy and antifungal strategy. Although the patients suffer of digestive symptoms, intestinale complications are really less explored. Neutropenic enterocolitis (NE), cytomegalovirus (CMV) colitis, Clostridium difficile colitis, specific lesion, ischemic colitis are not well-known. No prospective study evaluate NE and these digestive complications which have high morbi-mortality rates.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT03450512
Lead Sponsor Centre Hospitalier Universitaire, Amiens
Conditions Acute Myeloid Leukemia
Enrollment 170 participants
Start Date 2019-01-14
Primary Completion 2024-11-11 (estimated)
Study Completion 2024-11-13 (estimated)
Updated on ClinicalTrials.gov 2024-07-10